サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：うっ血性心不全（CHF）市場- 成長、将来展望、競合分析、2023～2031年
市場調査レポート
商品コード
1355788

うっ血性心不全（CHF）市場- 成長、将来展望、競合分析、2023～2031年

Congestive Heart Failure (CHF) Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031

出版日
ページ情報
英文 119 Pages
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
うっ血性心不全（CHF）市場- 成長、将来展望、競合分析、2023～2031年
出版日: 2023年09月07日
発行: Acute Market Reports
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

うっ血性心不全（CHF）は心不全としても知られ、血液を効率的に送り出す心臓の能力が低下する慢性的な病状です。この病態は、心臓の筋肉が弱くなったり損傷したりすることで、体の必要量を満たすための酸素を含んだ血液の供給が不十分になることで起こります。その結果、体内のさまざまな部位に水分がたまり、息切れ、疲労、足や足首のむくみ（浮腫）、身体活動の困難などの症状が現れます。うっ血性心不全治療薬市場は、2023年から2031年の予測期間中にCAGR 14.5％で成長すると予想されます。心臓疾患の蔓延と医療技術の進歩が相まって、効果的なCHF治療薬への需要が維持されるであろう。規制上の課題は今後も続き、企業は複雑な承認プロセスを乗り切る必要があります。多様な患者のニーズに対応するためには、クラス別および販売チャネル別の市場セグメンテーションが引き続き重要です。

心臓疾患の有病率の上昇

CHF治療薬市場の主な促進要因のひとつは、世界の心臓病有病率の上昇です。世界保健機関（WHO）は、心血管疾患を世界の死亡原因の第一位としています。うっ血性心不全の罹患率の増加は、座りがちなライフスタイルや食生活の乱れといった要因によって悪化しており、効果的な治療オプションに対する需要が大幅に高まっています。人口の高齢化に伴い、心臓関連の病気の負担は増加し、市場の成長をさらに促進すると予測されています。

医療技術の進歩

CHF治療の状況は、医療技術の進歩によって一変しました。ドラッグデリバリーシステム、個別化医療アプローチ、新規化合物の開発における革新は、患者の転帰を著しく改善しました。特に、サクビトリル／バルサルタン（エントレスト）のイントロダクションは、駆出率が低下した心不全の管理に画期的な進歩をもたらしました。このような進歩は、治療の有効性を高めるだけでなく、医療従事者や患者が利用できる治療の選択肢を拡大しました。

早期診断と早期治療の重視

心臓疾患の早期診断とタイムリーな治療を促進する取り組みは、CHF治療薬市場にプラスの影響を与えています。ヘルスケア機関や政府による心臓の健康や早期介入の利点に関する意識向上への取り組みが、患者の意識向上につながっています。心不全を早期に発見することで、医療従事者は病気の進行を防ぎ、生活の質全体を向上させる治療戦略を実施することができます。このような努力の積み重ねが、CHF治療薬の需要を押し上げています。

厳しい規制要件

CHF治療薬市場は成長を遂げる一方で、厳しい規制要件がもたらす課題にも遭遇しています。新薬の開発と承認取得のプロセスは複雑で時間がかかります。FDAやEMAなどの規制機関は、新薬候補に厳格な安全性と有効性の基準を課しており、開発期間の長期化とコストの上昇を招いています。規制状況を乗り切ることは、中小の製薬会社にとっては特に困難であり、市場成長の抑制要因となっています。

アンジオテンシン2受容体拮抗薬がクラス別市場を独占

2022年には、アンジオテンシン2受容体拮抗薬（ARB）が最も高い売上を記録しました。アンジオテンシン2受容体拮抗薬は、血管の収縮や体液貯留を引き起こすホルモンであるアンジオテンシンIIの作用を阻害することで効果を発揮する薬物です。これらの作用を阻害することで、ARBは血管を弛緩させ、血圧を下げ、心臓の負担を軽減します。ARBはCHFや高血圧などの関連疾患の管理によく処方されます。ACE阻害薬、β遮断薬、利尿薬などの他の薬剤と併用されることも多く、心不全患者に対する包括的な治療が行われます。これらの薬剤は症状を改善し、心臓のポンプ機能を高め、全体としてより良い病態管理に貢献します。アンジオテンシン2受容体拮抗薬は、その確立された有効性と広範な使用により、これまでCHF治療薬市場で大きな収益をあげてきました。アンジオテンシン2受容体拮抗薬は、心不全治療の様々な局面に対応できることから、多くの患者にとって治療レジメンの重要な構成要素となっています。しかし、各薬剤クラスが生み出す収益は、市場力学、価格設定、患者の嗜好、新しい治療選択肢の出現などの要因によって変動する可能性があることに留意することが重要です。

病院薬局が流通チャネル別市場を独占

2022年には、病院薬局が最も高い売上を記録しました。病院内薬局は、入院患者と外来患者の両方に薬を調剤する病院内のヘルスケア施設です。これらの薬局は、CHFを含む急性疾患の患者に必要不可欠な医薬品への即時アクセスを提供するという重要な役割を担っています。病院内の薬局では、心不全治療薬を含む幅広い種類の薬剤を扱っていることが多く、医療専門家の監督のもと、患者が適切な薬剤と用量を受け取れるようにしています。重症の心不全やその合併症で入院している患者さんには、直接静脈内注射や筋肉内注射が行われることもあり、病院内薬局はそのような患者さんにも対応しています。

北米が世界のリーダーであり続ける

CHF治療薬市場の地理的動向は、地域によって異なるパターンを示しています。CAGRが最も高い地域はアジア太平洋で、医療インフラ整備の進展、高齢者人口の増加、高血圧や糖尿病などの危険因子の蔓延といった要因が複合的に作用しています。北米は、確立されたヘルスケアシステム、多額の医療費、研究開発活動への重点的な取り組みにより、常に最高の売上シェアを維持しています。

競合動向と主要戦略

競合情勢が激しいCHF治療薬市場において、大手企業は市場での存在感を維持し、イノベーションを推進するために様々な戦略を採用しています。Bayer AG、Novartis AG、Merck &co., Inc.、Astrazeneca、Bristol-Myers Squibb Company、Amgen Inc.、BoehringerIngelheiminternationalGmbh、Pfizer, Inc.、Johnson &Johnson Services, Inc.、大塚製薬株式会社、Eli Lilly and Company、Novo Nordiska/Sのような注目すべき企業は、ポートフォリオを拡大し、市場でのリーチを強化するために、合併、買収、提携、製品発売を進めてきました。これらの企業はまた、精密治療、個別化医療アプローチ、患者転帰の改善に焦点を当てた研究開発にも多額の投資を行っています。

目次

第1章 序文

  • レポート内容
    • 報告書の目的
    • 対象者
    • 主な提供商品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ-二次調査
    • フェーズⅡ-一次調査
    • フェーズⅢ-有識者レビュー
    • 前提条件
    • 採用したアプローチ

第2章 エグゼクティブサマリー

第3章 うっ血性心不全（CHF）市場：競合分析

  • 主要ベンダーの市場での位置付け
  • ベンダーが採用する戦略
  • 主要な産業戦略
  • ティア分析：2022 vs 2031

第4章 うっ血性心不全（CHF）市場：マクロ分析と市場力学

  • イントロダクション
  • 世界のうっ血性心不全（CHF）市場金額 2021-2031
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析

第5章 うっ血性心不全（CHF）市場：薬剤クラス別 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • ACE阻害剤
    • アンジオテンシン2受容体遮断薬
    • ベータブロッカー
    • 利尿薬
    • アルドステロン拮抗薬
    • 変力剤
    • その他

第6章 うっ血性心不全（CHF）市場：流通チャネル別 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第7章 北米のうっ血性心不全（CHF）市場 2021-2031

  • 市場概要
  • うっ血性心不全（CHF）市場：薬剤クラス別 2021-2031
  • うっ血性心不全（CHF）市場：流通チャネル別 2021-2031
  • うっ血性心不全（CHF）市場：地域別 2021-2031
    • 北米
      • 米国
      • カナダ
      • その他北米地域

第8章 英国と欧州連合のうっ血性心不全（CHF）市場 2021-2031

  • 市場概要
  • うっ血性心不全（CHF）市場：薬剤クラス別 2021-2031
  • うっ血性心不全（CHF）市場：流通チャネル別 2021-2031
  • うっ血性心不全（CHF）市場：地域別 2021-2031
    • 英国と欧州連合
      • 英国
      • ドイツ
      • スペイン
      • イタリア
      • フランス
      • その他欧州地域

第9章 アジア太平洋のうっ血性心不全（CHF）市場 2021-2031

  • 市場概要
  • うっ血性心不全（CHF）市場：薬剤クラス別 2021-2031
  • うっ血性心不全（CHF）市場：流通チャネル別 2021-2031
  • うっ血性心不全（CHF）市場：地域別 2021-2031
    • アジア太平洋
      • 中国
      • 日本
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域

第10章 ラテンアメリカのうっ血性心不全（CHF）市場 2021-2031

  • 市場概要
  • うっ血性心不全（CHF）市場：薬剤クラス別 2021-2031
  • うっ血性心不全（CHF）市場：流通チャネル別 2021-2031
  • うっ血性心不全（CHF）市場：地域別 2021-2031
    • ラテンアメリカ
      • ブラジル
      • メキシコ
      • その他ラテンアメリカ地域

第11章 中東・アフリカのうっ血性心不全（CHF）市場 2021-2031

  • 市場概要
  • うっ血性心不全（CHF）市場：薬剤クラス別 2021-2031
  • うっ血性心不全（CHF）市場：流通チャネル別 2021-2031
  • うっ血性心不全（CHF）市場：地域別 2021-2031
    • 中東・アフリカ
      • GCC
      • アフリカ
      • その他中東・アフリカ地域

第12章 企業プロファイル

  • Bayer AGNovartis AG
  • Merck & co. Inc.
  • Astrazeneca
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • BoehringerIngelheiminternationalGmbh
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • Eli Lilly and Company
  • Novo Nordiska/S
  • その他の主要企業
図表

List of Tables

  • TABLE 1 Global Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 2 Global Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 3 North America Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 4 North America Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 5 U.S. Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 6 U.S. Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 7 Canada Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 8 Canada Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 9 Rest of North America Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 10 Rest of North America Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 11 UK and European Union Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 12 UK and European Union Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 13 UK Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 14 UK Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 15 Germany Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 16 Germany Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 17 Spain Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 18 Spain Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 19 Italy Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 20 Italy Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 21 France Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 22 France Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 23 Rest of Europe Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 24 Rest of Europe Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 25 Asia Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 26 Asia Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 27 China Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 28 China Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 29 Japan Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 30 Japan Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 31 India Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 32 India Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 33 Australia Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 34 Australia Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 35 South Korea Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 36 South Korea Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 37 Latin America Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 38 Latin America Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 39 Brazil Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 40 Brazil Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 41 Mexico Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 42 Mexico Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 43 Rest of Latin America Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 44 Rest of Latin America Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 45 Middle East and Africa Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 46 Middle East and Africa Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 47 GCC Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 48 GCC Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 49 Africa Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 50 Africa Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Congestive Heart Failure (CHF) Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Congestive Heart Failure (CHF) Market: Quality Assurance
  • FIG. 5 Global Congestive Heart Failure (CHF) Market, By Drug Class, 2022
  • FIG. 6 Global Congestive Heart Failure (CHF) Market, By Distribution Channel, 2022
  • FIG. 7 Global Congestive Heart Failure (CHF) Market, By Geography, 2022
  • FIG. 8 Market Geographical Opportunity Matrix - Global Congestive Heart Failure (CHF) Market, 2022

FIG. 9Market Positioning of Key Congestive Heart Failure (CHF) Market Players, 2022

FIG. 10Global Congestive Heart Failure (CHF) Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

  • FIG. 11 Global Congestive Heart Failure (CHF) Market, By Drug Class, 2022 Vs 2031, %
  • FIG. 12 Global Congestive Heart Failure (CHF) Market, By Distribution Channel, 2022 Vs 2031, %
  • FIG. 13 U.S. Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 14 Canada Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 15 Rest of North America Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 16 UK Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 17 Germany Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 18 Spain Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 19 Italy Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 20 France Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 21 Rest of Europe Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 22 China Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 23 Japan Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 24 India Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 25 Australia Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 26 South Korea Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 27 Rest of Asia Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 28 Brazil Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 29 Mexico Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 30 Rest of Latin America Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 31 GCC Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 32 Africa Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 33 Rest of Middle East and Africa Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
目次
Product Code: 139808-09-23

Congestive heart failure (CHF), also known as heart failure, is a chronic medical condition in which the heart's ability to pump blood efficiently is compromised. This condition occurs when the heart muscles become weakened or damaged, leading to an inadequate supply of oxygenated blood to meet the body's needs. As a result, fluid may accumulate in various parts of the body, causing symptoms such as shortness of breath, fatigue, swelling in the legs and ankles (edema), and difficulty performing physical activities. The congestive heart failure drug market is expected to grow at a CAGR of 14.5% during the forecast period of 2023 to 2031. The prevalence of heart diseases, coupled with ongoing advancements in medical technology, will sustain the demand for effective CHF treatments. Regulatory challenges will persist, requiring companies to navigate complex approval processes. Market segmentation by class and distribution channels will remain instrumental in catering to diverse patient needs.

Rising Prevalence of Heart Diseases

One of the primary drivers of the CHF drugs market is the escalating prevalence of heart diseases worldwide. The World Health Organization (WHO) has identified cardiovascular diseases as the leading cause of mortality globally. The growing incidence of congestive heart failure, exacerbated by factors like sedentary lifestyles and poor dietary habits, has substantially increased the demand for effective treatment options. As the population ages, the burden of heart-related ailments is projected to rise, further fueling the market's growth.

Advancements in Medical Technology

The landscape of CHF treatment has been revolutionized by advancements in medical technology. Innovations in drug delivery systems, personalized medicine approaches, and the development of novel drug compounds have significantly improved patient outcomes. Notably, the introduction of sacubitril/valsartan (Entresto) has marked a breakthrough in managing heart failure with reduced ejection fraction. Such advancements have not only enhanced the efficacy of treatments but have also expanded the treatment options available to healthcare providers and patients.

Focus on Early Diagnosis and Treatment

Efforts to promote early diagnosis and timely treatment of heart conditions have had a positive impact on the CHF drugs market. Initiatives by healthcare organizations and governments to raise awareness about heart health and the benefits of early intervention have led to increased patient awareness. By identifying heart failure in its early stages, medical professionals can implement treatment strategies that prevent disease progression and improve overall quality of life. These efforts have collectively driven the demand for CHF drugs.

Stringent Regulatory Requirements

While the CHF drugs market has experienced growth, it has also encountered challenges posed by stringent regulatory requirements. The process of developing and gaining approval for new drugs is complex and time-consuming. Regulatory agencies such as the FDA and EMA impose rigorous safety and efficacy standards on new drug candidates, leading to prolonged development timelines and elevated costs. Navigating the regulatory landscape can be particularly challenging for smaller pharmaceutical companies, acting as a restraint on market growth.

Angiotensin 2 Receptor Blockers Dominated Market by Class

In 2022, Angiotensin 2 Receptor Blockers (ARBs) held highest revenue. Angiotensin 2 Receptor Blockers are a class of medications that work by blocking the effects of the hormone angiotensin II, which can lead to blood vessel constriction and fluid retention. By blocking these effects, ARBs help relax blood vessels, reduce blood pressure, and decrease the workload on the heart. ARBs are commonly prescribed to manage CHF and related conditions, such as hypertension. They are often used in combination with other medications, such as ACE inhibitors, beta blockers, and diuretics, to provide comprehensive treatment for heart failure patients. These medications can help improve symptoms, enhance the heart's pumping efficiency, and overall contribute to better management of the condition. Due to their established efficacy and widespread use, Angiotensin 2 Receptor Blockers have historically generated substantial revenue in the CHF drugs market. Their ability to address multiple aspects of heart failure management makes them a critical component of treatment regimens for many patients. However, it's important to note that the revenue generated by each drug class can vary based on factors such as market dynamics, pricing, patient preferences, and the emergence of newer treatment options.

Hospital Pharmacies Dominates Market by Distribution Channel

In 2022, Hospital Pharmacies held highest revenue. Hospital Pharmacies are healthcare facilities within hospitals that dispense medications to both inpatients and outpatients. These pharmacies play a crucial role in providing immediate access to essential medications for patients with acute conditions, including CHF. Hospital Pharmacies often have a wide range of medications available, including those for treating heart failure, and they ensure that patients receive the right medications and dosages under the supervision of healthcare professionals. Patients hospitalized due to severe CHF or related complications may have their medications administered directly through intravenous (IV) or intramuscular (IM) injections, which are facilitated by Hospital Pharmacies.

North America Remains as the Global Leader

The geographic trends in the CHF drugs market reveal varying patterns across regions. The region with the highest CAGR is Asia-Pacific, driven by a combination of factors such as increasing healthcare infrastructure development, a rising geriatric population, and the prevalence of risk factors like hypertension and diabetes. North America has consistently held the highest revenue share, attributed to its well-established healthcare systems, significant healthcare expenditure, and a robust focus on research and development activities.

Competitive Trends and Key Strategies

In the fiercely Competitive Landscape of the CHF drugs market, leading players have adopted diverse strategies to maintain their market presence and drive innovation. Notable players like Bayer AG,Novartis AG, Merck & co., Inc., Astrazeneca, Bristol-Myers Squibb Company, Amgen Inc., BoehringerIngelheiminternationalGmbh, Pfizer, Inc., Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, and Novo Nordiska/S have pursued mergers, acquisitions, collaborations, and product launches to expand their portfolios and enhance their market reach. These companies are also investing heavily in research and development endeavors, focusing on precision therapies, personalized medicine approaches, and improved patient outcomes.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofCongestive Heart Failure (CHF) market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Congestive Heart Failure (CHF) market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • ACE Inhibitors
  • Angiotensin 2 Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Aldosterone Antagonists
  • Inotropes
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Congestive Heart Failure (CHF) market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Congestive Heart Failure (CHF) market?
  • Which is the largest regional market for Congestive Heart Failure (CHF) market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Congestive Heart Failure (CHF) market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Congestive Heart Failure (CHF) market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Congestive Heart Failure (CHF) Market
  • 2.2. Global Congestive Heart Failure (CHF) Market, By Drug Class, 2022 (US$ Million)
  • 2.3. Global Congestive Heart Failure (CHF) Market, By Distribution Channel, 2022 (US$ Million)
  • 2.4. Global Congestive Heart Failure (CHF) Market, By Geography, 2022 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2022

3. Congestive Heart Failure (CHF) Market: Competitive Analysis

  • 3.1. Market Positioning of Key Congestive Heart Failure (CHF) Market Vendors
  • 3.2. Strategies Adopted by Congestive Heart Failure (CHF) Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Congestive Heart Failure (CHF) Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Congestive Heart Failure (CHF) Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. ACE Inhibitors
    • 5.3.2. Angiotensin 2 Receptor Blockers
    • 5.3.3. Beta Blockers
    • 5.3.4. Diuretics
    • 5.3.5. Aldosterone Antagonists
    • 5.3.6. Inotropes
    • 5.3.7. Others

6. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Online Pharmacies

7. North America Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 7.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 7.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 7.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 7.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 7.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

8. UK and European Union Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 8.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 8.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.4.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.5.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.6.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

9. Asia Pacific Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 9.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 9.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.4.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.5.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.6.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

10. Latin America Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 10.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 10.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 10.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 10.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 10.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

11. Middle East and Africa Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 11.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 11.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 11.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 11.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 11.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

12. Company Profile

  • 12.1. Bayer AG,Novartis AG
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Merck & co., Inc.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Astrazeneca
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Bristol-Myers Squibb Company
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Amgen Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. BoehringerIngelheiminternationalGmbh
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Pfizer, Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Johnson & Johnson Services, Inc.
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Otsuka Pharmaceutical Co., Ltd.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Eli Lilly and Company
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Novo Nordiska/S
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
  • 12.12. Other Notable Players
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Initiatives